肌醇预防妊娠期糖尿病:矛盾试验对临床的启示
本文批判性评价了已发表荟萃分析中随机对照试验的临床与方法学特征,探讨肌醇预防妊娠期糖尿病试验结果差异的原因。研究发现人群特征、治疗起始时机和补充方案存在差异,现有证据无法确定最佳目标人群、方案或时机,需开展关注新生儿结局的充分把握度试验。
要点
- 试验间人群特征、治疗起始时机和补充方案差异大,可能导致结果不一致
- 现有证据无法确定肌醇预防妊娠期糖尿病的最佳目标人群、方案或时机
- 短期耐受性一致良好,但长期新生儿结局和安全数据有限
核心结论
- 近期荟萃分析提示肌醇补充与妊娠期糖尿病风险降低相关,但研究间异质性大,证据尚不足以确立最佳目标人群、补充方案或治疗起始时机。
研究设计与样本
- 本文为临床视角的批判性评价,对已发表荟萃分析中纳入的随机对照试验的临床和方法学特征进行评价,以探讨结果变异的原因。
主要发现
- 试验间人群特征存在明显差异,包括糖尿病家族史、既往妊娠期糖尿病史和超重或肥胖的患病率。
- 试验在治疗起始时机(第14周前或后)和补充方案上也存在差异。
- 现有证据无法就治疗效应修饰得出结论,因为研究水平分析不能区分真实治疗效应差异与统计把握度或其他研究特征的差异。
- 短期耐受性一致报告良好,但长期新生儿结局罕见报告,安全性数据仍有限。
临床怎么用
- 临床解读肌醇预防妊娠期糖尿病的证据时,应认识到试验间人群、时机和方案差异可能导致结果不一致,不能简单推广。
- 现有证据尚不能确定肌醇补充的最佳目标人群、补充方案或治疗起始时机,临床决策需个体化并关注安全性数据局限。
局限性
- 研究水平分析无法区分真实治疗效应差异与统计把握度或其他研究特征的差异。
- 长期新生儿结局罕见报告,安全性数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A recent meta-analysis reported that myo-inositol supplementation was associated with a reduced risk of gestational diabetes mellitus. However, the primary outcome showed substantial between-study heterogeneity, complicating the interpretation and clinical applicability of the evidence. OBJECTIVE: To discuss why randomized trials may have produced different results and identify the information needed to guide future research and clinical interpretation. STUDY DESIGN: We critically appraised the clinical and methodological characteristics of the randomized controlled trials included in the published meta-analysis to explore factors that may have contributed to their variability in results. RESULTS: Substantial differences were found in population characteristics, including the prevalence of a family history of diabetes, previous gestational diabetes mellitus, and overweight or obesity. Trials also differed in the timing of treatment initiation (before or after the 14th week) and in their supplementation protocols. The available evidence does not allow conclusions regarding treatment effect modification, because study-level analyses cannot distinguish true differences in treatment effects from differences in statistical power or other study characteristics. Short-term tolerability has been consistently reported; however, long-term neonatal outcomes have rarely been reported, and safety data remain limited. CONCLUSION: The recent meta-analysis provided a signal of benefit of myo-inositol for prevention of gestational diabetes mellitus. This clinical perspective identifies and discusses clinical and methodological differences that may have contributed to the variability in results across trials. However, the available evidence does not establish the optimal target population, supplementation protocol, or timing of treatment initiation. Adequately powered randomized trials focusing on short- and long-term neonatal outcomes are needed to better define the efficacy and safety of myo-inositol for the prevention of gestational diabetes mellitus.
引用
- Lecis S, D'Anna R, Garzon S, et al. Myo-inositol to prevent gestational diabetes: "What do conflicting trials tell clinicians?". Am J Obstet Gynecol. 2026. PMID: 42864184. doi:10.1016/j.ajog.2026.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。